Proteomics International Laboratories Director James Williams Acquires 120,000 Shares at $0.10 Each

Anjali Anand

11 November 2026 12:32 PM AEDT

Proteomics International Laboratories Director James Williams Acquires 120,000 Shares at $0.10 Each

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Proteomics International Laboratories Ltd (ASX:PIQ) has disclosed a change in the relevant interests of director James Williams, following an on-market purchase of 120,000 fully paid ordinary shares at an average price of $0.10 per share, acquired indirectly through JAMPASO PTY LTD as trustee for the JAMPASO SF account on 10 November 2026.

Key Points

Director James Williams acquired 120,000 fully paid ordinary shares indirectly via JAMPASO PTY LTD on 10 November 2026
Shares were purchased on-market at an average price of $0.10 per share
Williams holds direct interests of 125,000 Director E options and 125,000 Director F options, unchanged by this transaction
Prior to this change, Williams held nil securities in the indirect interest; following the change, the indirect holding stands at 120,000 fully paid ordinary shares
The transaction did not occur during a closed period requiring prior written clearance

On-Market Share Purchase by Director James Williams

According to the filing lodged with ASX, director James Williams completed an on-market purchase of 120,000 fully paid ordinary shares in Proteomics International Laboratories Ltd on 10 November 2026. The shares were acquired indirectly through the registered entity JAMPASO PTY LTD, acting in the capacity of the JAMPASO SF account. The average purchase price was $0.10 per share. Prior to this transaction, Williams held no securities through this indirect interest. The previous director's interest notice for Williams was dated 21 November 2024.

Director's Securities Holdings After the Change

Following the on-market purchase, the filing discloses that James Williams now holds, indirectly through JAMPASO PTY LTD, 120,000 fully paid ordinary shares in Proteomics International Laboratories Ltd. His direct holdings remain unchanged and consist of 125,000 Director E options and 125,000 Director F options. No securities were disposed of as part of this transaction, and no changes to director interests in contracts were reported. Part 2 of the filing records all contract-related fields as not applicable.

Closed Period and Compliance Disclosure

The filing states that the interests in securities detailed in the notice were not traded during a closed period in which prior written clearance was required. As a result, the questions relating to whether prior written clearance was obtained and the date of any such clearance are both recorded as not applicable in the disclosure. The notice was submitted by Proteomics International Laboratories Ltd, ABN 78 169 979 971, as agent for the director in accordance with listing rule 3.19A.2 and section 205G of the Corporations Act.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.